Product image of Kolistimetatnatrij Accord (Colistimethate Sodium) supplied by GNH India

Kolistimetatnatrij Accord

Active Ingredient:
Colistimethate Sodium
Origin:
EU

Kolistimetatnatrij Accord (Colistimethate Sodium)

Colistimethate sodium, the active ingredient in Kolistimetatnatrij Accord, is a polymyxin antibiotic presented as an intravenous formulation for use in severe Gram‑negative bacterial infections, including those caused by Pseudomonas aeruginosa. It is administered under medical supervision to patients with life‑threatening infections where other antibiotics may be ineffective.

GNH India supplies Kolistimetatnatrij Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Accord Healthcare Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kolistimetatnatrij Accord is used to treat infections caused by susceptible Gram‑negative bacteria, acting on the bacterial cell membrane to eradicate the pathogen.

  • Pseudomonas aeruginosa infections: eradicates the pathogen and helps resolve the infection.
  • Hospital‑acquired pneumonia: reduces bacterial load and improves respiratory function.
  • Ventilator‑associated pneumonia: targets resistant Gram‑negative organisms to aid recovery.
  • Bloodstream infections (septicemia): clears bacteremia and supports systemic infection control.

How It Works

  • Colistimethate sodium binds to the lipopolysaccharide component of the outer membrane of Gram‑negative bacteria, displacing calcium and magnesium ions. This interaction disrupts membrane integrity, increases permeability, and leads to leakage of cellular contents, ultimately causing bacterial cell death.

Side Effects

Colistimethate sodium may cause a range of adverse reactions, from mild to severe. Monitoring patients for these effects is essential during therapy.

Common Side Effects

  • Nephrotoxicity: elevated serum creatinine and reduced renal function.
  • Neurotoxicity: paresthesia, dizziness, or headache.
  • Nausea and vomiting: gastrointestinal discomfort.
  • Rash or mild skin irritation.
  • Fever: transient temperature elevation.

Serious or Rare Side Effects

  • Acute renal failure: rapid decline in kidney function requiring intervention.
  • Respiratory paralysis: especially when combined with neuromuscular blockers.
  • Anaphylaxis: severe allergic reaction with hypotension and airway compromise.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
  • Ototoxicity: hearing loss or tinnitus.

Precautions & Warnings

When using Kolistimetatnatrij Accord, clinicians should consider several safety measures to minimize risk.

  • Renal monitoring: assess serum creatinine and urine output regularly.
  • Neurotoxicity vigilance: watch for signs of peripheral neuropathy or seizures.
  • Pre‑existing kidney disease: adjust therapy and monitor closely.
  • Neuromuscular disorders: avoid concurrent use with agents that may enhance blockade.
  • Concomitant nephrotoxic drugs: limit or monitor dosage when used together.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Colistimetatnatrij Accord can interact with other medicines, affecting safety and efficacy.

Major Interactions (Avoid)

  • Aminoglycosides: additive nephrotoxicity.
  • Loop diuretics: increased risk of renal impairment.
  • Vancomycin: heightened renal toxicity.
  • Neuromuscular blocking agents: enhanced respiratory muscle weakness.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may worsen kidney function.
  • ACE inhibitors or ARBs: potential for reduced renal clearance.
  • Other nephrotoxic antibiotics: monitor renal parameters closely.

Frequently Asked Questions

Kolistimetatnatrij Accord contains colistimethate sodium, a polymyxin antibiotic indicated for the treatment of severe infections caused by susceptible Gram‑negative bacteria, such as Pseudomonas aeruginosa, especially in hospital‑acquired or ventilator‑associated pneumonia and bloodstream infections.

Colistimethate sodium binds to the lipopolysaccharide layer of Gram‑negative bacterial membranes, displacing stabilising cations. This disrupts membrane integrity, increases permeability, and leads to leakage of cellular contents, ultimately causing bacterial cell death.

The dosage of Kolistimetatnatrij Accord is determined by the prescribing clinician based on infection severity, patient weight, renal function, and susceptibility data. The prescriber sets the appropriate dose and administration schedule.

Safety data for colistimethate sodium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Kolistimetatnatrij Accord (colistimethate sodium) is a pro‑drug of colistin, similar in spectrum to polymyxin B but differs in pharmacokinetics and dosing. It is often chosen for infections where resistance to other classes exists, though both agents share comparable efficacy and risk profiles, requiring careful renal monitoring.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Use aseptic technique during preparation and administer promptly after reconstitution.

Kolistimetatnatrij Accord is administered intravenously by a healthcare professional. The reconstituted solution is infused over a prescribed period, typically via a controlled infusion pump, following aseptic preparation guidelines.

The most serious risks include acute renal failure, neurotoxicity leading to seizures or respiratory paralysis, severe allergic reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Immediate medical attention is required if these occur.

Patients with known hypersensitivity to colistimethate sodium or other polymyxins should avoid the drug. Caution is advised in individuals with pre‑existing renal impairment, neuromuscular disorders, or those receiving concurrent nephrotoxic or neuromuscular‑blocking agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Colistimethate Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT